- Home
- ELDN vs CNTB Comparison
ELDN vs CNTB Comparison
Compare ELDN & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELDN | CNTB |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.8M | 128.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ELDN | CNTB |
|---|---|---|
| Price | $1.64 | $2.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $8.50 | $8.50 |
| AVG Volume (30 Days) | ★ 1.1M | 314.4K |
| Earning Date | 11-14-2025 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $762,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $38,289.22 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.35 | $0.51 |
| 52 Week High | $4.98 | $3.28 |
Technical Indicators
Market Signals| Indicator | ELDN | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 40.79 | 48.07 |
| Support Level | $1.55 | $2.03 |
| Resistance Level | $1.75 | $2.38 |
| Average True Range (ATR) | 0.10 | 0.19 |
| MACD | 0.06 | -0.06 |
| Stochastic Oscillator | 59.65 | 36.36 |
Price Performance
Historical ComparisonAbout ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.